BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17671219)

  • 1. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.
    Wei S; Kryczek I; Edwards RP; Zou L; Szeliga W; Banerjee M; Cost M; Cheng P; Chang A; Redman B; Herberman RB; Zou W
    Cancer Res; 2007 Aug; 67(15):7487-94. PubMed ID: 17671219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
    Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
    J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
    Berntsen A; Brimnes MK; thor Straten P; Svane IM
    J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
    Kryczek I; Wei S; Zhu G; Myers L; Mottram P; Cheng P; Chen L; Coukos G; Zou W
    Cancer Res; 2007 Sep; 67(18):8900-5. PubMed ID: 17875732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.
    Javeed A; Zhang B; Qu Y; Zhang A; Sun C; Zhang L; Liu J; Zeng C; Zhao Y
    Transpl Immunol; 2009 Mar; 20(4):253-60. PubMed ID: 19146957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner.
    Yuan XL; Chen L; Li MX; Dong P; Xue J; Wang J; Zhang TT; Wang XA; Zhang FM; Ge HL; Shen LS; Xu D
    Clin Immunol; 2010 Mar; 134(3):277-88. PubMed ID: 19900843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy.
    Sumida Y; Nakamura K; Kanayama K; Akiho H; Teshima T; Takayanagi R
    Cytotherapy; 2008; 10(7):698-710. PubMed ID: 18985477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
    Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
    Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.
    Yan B; Ye S; Chen G; Kuang M; Shen N; Chen S
    Arthritis Rheum; 2008 Mar; 58(3):801-12. PubMed ID: 18311820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.
    Wang S; Jiang J; Guan Q; Lan Z; Wang H; Nguan CY; Jevnikar AM; Du C
    Transpl Immunol; 2008 May; 19(2):93-102. PubMed ID: 18503884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome.
    Chen L; Yang P; Zhou H; He H; Ren X; Chi W; Wang L; Kijlstra A
    Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3475-82. PubMed ID: 18421089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
    Aarts-Riemens T; Emmelot ME; Verdonck LF; Mutis T
    Eur J Immunol; 2008 May; 38(5):1381-90. PubMed ID: 18412171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
    Brandenburg S; Takahashi T; de la Rosa M; Janke M; Karsten G; Muzzulini T; Orinska Z; Bulfone-Paus S; Scheffold A
    Eur J Immunol; 2008 Jun; 38(6):1643-53. PubMed ID: 18493984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma.
    Enarsson K; Lundgren A; Kindlund B; Hermansson M; Roncador G; Banham AH; Lundin BS; Quiding-Järbrink M
    Clin Immunol; 2006 Dec; 121(3):358-68. PubMed ID: 16934529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis.
    Lewkowicz N; Lewkowicz P; Dzitko K; Kur B; Tarkowski M; Kurnatowska A; Tchórzewski H
    J Oral Pathol Med; 2008 Sep; 37(8):454-61. PubMed ID: 18318707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
    Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
    Sharma S; Yang SC; Zhu L; Reckamp K; Gardner B; Baratelli F; Huang M; Batra RK; Dubinett SM
    Cancer Res; 2005 Jun; 65(12):5211-20. PubMed ID: 15958566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.